Hanmi Pharmaceutical, a South Korean company, successfully licensed one of its obesity drug candidates to the multinational giant Hoffmann-La Roche on August 1, 2026.
1 report, 1 independent
Updated Aug 1
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Hanmi Pharmaceutical, a South Korean company, successfully licensed one of its obesity drug candidates to the multinational giant Hoffmann-La Roche on August 1, 2026.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
Hanmi Pharmaceutical
South Korean pharmaceutical company
Nothing else this week.
-
Hoffmann-La Roche
Swiss healthcare company